Drug Profile
Agenmestencel-L - Minaris Regenrative Medicine
Alternative Names: MSC apceth 111; MSC_apceth_111Latest Information Update: 06 Jan 2021
Price :
$50
*
At a glance
- Originator Apceth
- Developer Apceth Biopharma
- Class Gene therapies; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Gastrointestinal cancer
Most Recent Events
- 04 Oct 2019 Agenmestencel-L is still in clinical trials for Gastrointestinal cancer in Germany (IV) (Apceth website, September 2019)
- 06 Apr 2017 Apceth terminates a phase I/II trial in Gastrointestinal cancer (Late-stage disease, Recurrent, Metastatic disease, Combination therapy) in Germany (EudraCT2015-000520-29) prior to March 2017